Indicated as replacement therapy for patients with primary immunodeficiency, age 2 and older.
Indications include humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Given weekly provides lower peak serum levels and generally higher trough levels than monthly IG therapies.
Thrombosis may occur with immune globulin products.
Thrombosis risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors.
Given daily or up to once every two weeks 20% Hizentra delivers an Ig dose in half the volume of 10% Ig products.
Administered subcutaneously only.
IgA-deficient patients with anti-IgA antibodies may be a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.
After appropriate training patients can self-administer this drug.